



**INVITATION**

(for Kangaroo Group Members and Guests)

**VIRTUAL– DEBATE**

Wednesday, **27 January 2021** a Debate from 13:00 to 14:30 hrs

**“The European Pharmaceutical Strategy – enabling patient access to gene therapy innovation?”**

*Gene therapy holds the promise to transform the lives of people who suffer from debilitating and life-threatening genetic disorders. However, these innovative therapies face a number of barriers to reach the European patients who stand to benefit from them. The Pharmaceutical Strategy for Europe, published on 25 November 2020, recognises gene therapy as a 'major milestone' of progress in healthcare. The Strategy, which aims to ensure access to affordable medicines and address unmet medical needs while also supporting innovation and competitiveness in the EU, highlights that gene therapy requires 'a new business model to address the shift in cost from chronic to one-time treatment.' How can the Pharmaceutical Strategy support in developing and implementing effective policies and legislation to ensure rapid patient access to these transformative therapies?*

**Welcome and Chair:**

Michael GAHLER MEP, President of the Kangaroo Group

**Speakers:**

Claudia GAMON MEP, Renew Europe/Austria, Member of the Committee on Industry, Research and Energy

Adam HUTCHINGS, Managing Director, DOLON

*Other Speakers to be confirmed*

***This debate will be conducted via Zoom and hosted by the Kangaroo Group***

Please reply to the Kangaroo Group's Brussels office, whether you will attend or not  
by e-mail: [office@kangaroorgroup.eu](mailto:office@kangaroorgroup.eu)

Name: ..... Email: .....

Organisation + Title: .....

Yes, I will attend

No, I will not attend